{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:33:52Z","timestamp":1794670432611,"version":"4.9.1"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Swiss Heart Foundation","award":["FF23084"],"award-info":[{"award-number":["FF23084"]}],"id":[{"id":"https:\/\/ror.org\/01k789405","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Swiss Heart Foundation","award":["FF19045"],"award-info":[{"award-number":["FF19045"]}],"id":[{"id":"https:\/\/ror.org\/01k789405","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["310030_197557"],"award-info":[{"award-number":["310030_197557"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012654","name":"Olga Mayenfisch Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012654","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013161","name":"Swiss Life Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013161","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kurt und Senta-Hermann Stiftung"},{"DOI":"10.13039\/501100008464","name":"EMDO Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008464","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Schweizerische Diabetes-Stiftung"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02774-w","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:12:29Z","timestamp":1751519549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Era","family":"Gorica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Di Venanzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Atzemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Alphard","family":"Kleeberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Grigorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besa","family":"Emini Veseli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafeeq A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas J.","family":"Flammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Niederseer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"1","key":"2774_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jacc.2009.03.037","volume":"54","author":"YT Tan","year":"2009","unstructured":"Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol. 2009;54(1):36\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2774_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.122.059280","volume":"146","author":"S Rosch","year":"2022","unstructured":"Rosch S, Kresoja KP, Besler C, Fengler K, Sch\u00f6ber AR, von Roeder M, et al. Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. Circulation. 2022;146(7):506\u201318.","journal-title":"Circulation"},{"key":"2774_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-025-10504-3","author":"B Pecchia","year":"2025","unstructured":"Pecchia B, Samuel R, Shah V, Newman E, Gibson GT. Mechanisms ofexercise intolerance in heart failure with preserved ejection fraction (HFpEF). Heart Fail Rev. 2025. https:\/\/doi.org\/10.1007\/s10741-025-10504-3.","journal-title":"Heart Fail Rev"},{"issue":"11","key":"2774_CR4","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/s41591-019-0644-7","volume":"25","author":"JJ Miranda","year":"2019","unstructured":"Miranda JJ, Barrientos-Guti\u00e9rrez T, Corvalan C, Hyder AA, Lazo-Porras M, Oni T, et al. Understanding the rise of cardiometabolic diseases in low- and middle-income countries. Nat Med. 2019;25(11):1667\u201379.","journal-title":"Nat Med"},{"key":"2774_CR5","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.05","volume":"9","author":"B Shahim","year":"2023","unstructured":"Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023;9: e11.","journal-title":"Card Fail Rev"},{"issue":"10431","key":"2774_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","volume":"403","author":"P Campbell","year":"2024","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024;403(10431):1083\u201392.","journal-title":"Lancet"},{"issue":"1","key":"2774_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002477","volume":"5","author":"R Samson","year":"2016","unstructured":"Samson R, Jaiswal A, Ennezat PV, Cassidy M, Le Jemtel TH. Clinical phenotypes in heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;5(1): e002477.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2774_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","volume":"20","author":"ND Wong","year":"2023","unstructured":"Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20(10):685\u201395.","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"2774_CR9","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","volume":"29","author":"F Lopez-Jimenez","year":"2022","unstructured":"Lopez-Jimenez F, Almahmeed W, Bays H, Cuevas A, Di Angelantonio E, le Roux CW, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the world heart federation and world obesity federation. Eur J Prev Cardiol. 2022;29(17):2218\u201337.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"2774_CR10","first-page":"4","volume":"49","author":"S Kenchaiah","year":"2017","unstructured":"Kenchaiah S, Chesebro JH. The epidemiologic association between obesity and heart failure. Am Coll Cardiol Ext Learn. 2017;49(8):4\u20136.","journal-title":"Am Coll Cardiol Ext Learn"},{"key":"2774_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132069","volume":"407","author":"Y Hong","year":"2024","unstructured":"Hong Y, Gao Z, Wei H, Wei Y, Qiu Z, Xiao J, et al. Bi-directional association of body size and composition with heart failure: a Mendelian randomization study. Int J Cardiol. 2024;407: 132069.","journal-title":"Int J Cardiol"},{"issue":"12","key":"2774_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"7","key":"2774_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V,et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2025;85(7):699\u2013706.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2774_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","volume":"24","author":"D Hullon","year":"2025","unstructured":"Hullon D, Subeh GK, Volkova Y, Janiec K, Trach A, Mnevets R. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF). Cardiovasc Diabetol. 2025;24(1):70.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2774_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/CIRCGENETICS.111.961367","volume":"4","author":"JL Hall","year":"2011","unstructured":"Hall JL, Terzic A. Heart failure transcriptome. Circ Cardiovasc Genet. 2011;4(5):469\u201371.","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"2774_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pcad.2018.07.012","volume":"61","author":"MA Alpert","year":"2018","unstructured":"Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and cardiac remodeling in adults: mechanisms and clinical implications. Prog Cardiovasc Dis. 2018;61(2):114\u201323.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"2774_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","volume":"18","author":"S Mishra","year":"2021","unstructured":"Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400\u201323.","journal-title":"Nat Rev Cardiol"},{"key":"2774_CR18","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858."},{"issue":"8","key":"2774_CR19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cardfail.2024.01.015","volume":"30","author":"GWM Walters","year":"2024","unstructured":"Walters GWM, Yeo JL, Bilak JM, Pepper C, Gulsin GS, Freeman SC, et al. The effectiveness of lifestyle interventions in heart failure with preserved ejection fraction: a systematic review and network meta-analysis. J Card Fail. 2024;30(8):994\u20131009.","journal-title":"J Card Fail"},{"issue":"7","key":"2774_CR20","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41366-020-0579-6","volume":"44","author":"S Carbone","year":"2020","unstructured":"Carbone S, Lavie CJ. Disparate effects of obesity on survival and hospitalizations in heart failure with preserved ejection fraction. Int J Obes (Lond). 2020;44(7):1543\u20135.","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"2774_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","volume":"10","author":"CE Hamo","year":"2024","unstructured":"Hamo CE, DeJong C, Hartshorne-Evans N, Lund LH, Shah SJ, Solomon S, et al. Heart failure with preserved ejection fraction. Nat Rev Dis Primers. 2024;10(1):55.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2774_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ehf2.12204","volume":"4","author":"MS Khan","year":"2017","unstructured":"Khan MS, Fonarow GC, Khan H, Greene SJ, Anker SD, Gheorghiade M, et al. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2017;4(4):402\u20138.","journal-title":"ESC Heart Fail"},{"key":"2774_CR23","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.23","volume":"9","author":"V Castiglione","year":"2023","unstructured":"Castiglione V, Gentile F, Ghionzoli N, Chiriac\u00f2 M, Panichella G, Aimo A, et al. Pathophysiological rationale and clinical evidence for neurohormonal modulation in heart failure with preserved ejection fraction. Card Fail Rev. 2023;9: e09.","journal-title":"Card Fail Rev"},{"issue":"20","key":"2774_CR24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2012.14785","volume":"308","author":"LH Lund","year":"2012","unstructured":"Lund LH,Benson L, Dahlstr\u00f6m U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308(20):2108\u201317.","journal-title":"JAMA"},{"issue":"11","key":"2774_CR25","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"16","key":"2774_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"4","key":"2774_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","volume":"12","author":"A Peikert","year":"2024","unstructured":"Peikert A, Bart BA, Vaduganathan M, Claggett BL, Kulac IJ, Kosiborod MN, et al. Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial. JACC Heart Fail. 2024;12(4):631\u201344.","journal-title":"JACC Heart Fail"},{"key":"2774_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.amjcard.2021.01.013","volume":"145","author":"HM Salah","year":"2021","unstructured":"Salah HM, Fudim M, Al\u2019Aref SJ, Khan MS, Almarzooq ZI, Devabhaktuni SR, et al. Meta-analysis of efficacy of sacubitril\/valsartan in heart failure with preserved ejection fraction. Am J Cardiol. 2021;145:165\u20138.","journal-title":"Am J Cardiol"},{"key":"2774_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.124.011306","author":"PM Thangaraj","year":"2025","unstructured":"Thangaraj PM, Oikonomou EK, Dhingra LS, Aminorroaya A, Jayaram R, Suchard MA, et al. Computational phenomapping of randomized clinical trial participants to enable assessment of their real-world representativeness and personalized inference. Circ Cardiovasc Qual Outcomes. 2025. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.124.011306.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"2774_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/CIRCULATIONAHA.120.045008","volume":"141","author":"B Bozkurt","year":"2020","unstructured":"Bozkurt B, Ezekowitz J. Substance and substrate: LVEF and sex subgroup analyses of PARAGON-HF and PARADIGM-HF trials. Circulation. 2020;141(5):362\u20136.","journal-title":"Circulation"},{"issue":"17","key":"2774_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med"},{"issue":"16","key":"2774_CR32","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"2","key":"2774_CR33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/ijms25020794","volume":"25","author":"L Stoicescu","year":"2024","unstructured":"Stoicescu L, Cri\u015fan D, Morgovan C, Avram L, Ghibu S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. Int J Mol Sci.2024;25(2):794.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2774_CR34","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, et al. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC Heart Fail. 2024;12(11):1814\u201326.","journal-title":"JACC Heart Fail"},{"issue":"20","key":"2774_CR35","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39(20):1770\u201380.","journal-title":"Eur Heart J"},{"issue":"12","key":"2774_CR36","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/eurjpc\/zwad140","volume":"30","author":"S Prausm\u00fcller","year":"2023","unstructured":"Prausm\u00fcller S, Weidenhammer A, Heitzinger G, Spinka G, Goliasch G, Arfsten H, et al. Obesity in heart failure with preserved ejection fraction with and without diabetes: risk factor or innocent bystander? Eur J Prev Cardiol. 2023;30(12):1247\u201354.","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"2774_CR37","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction. JACC. 2023;81(18):1810\u201334.","journal-title":"JACC"},{"issue":"8","key":"2774_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","volume":"6","author":"N Savji","year":"2018","unstructured":"Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The Association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail. 2018;6(8):701\u20139.","journal-title":"JACC Heart Fail"},{"key":"2774_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.trsl.2017.10.004","volume":"191","author":"C Li","year":"2018","unstructured":"Li C, Xu MM, Wang K, Adler AJ, Vella AT, Zhou B. Macrophage polarization and meta-inflammation. Transl Res. 2018;191:29\u201344.","journal-title":"Transl Res"},{"issue":"5","key":"2774_CR40","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3390\/ijms25052702","volume":"25","author":"J Girona","year":"2024","unstructured":"Girona J, Soler O, Samino S, Junza A, Mart\u00ednez-Micaelo N, Garc\u00eda-Altares M, et al. Lipidomics reveals myocardial lipid composition in a murine model of insulin resistance induced by a high-fat diet. Int J Mol Sci. 2024;25(5):2702.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2774_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41467-025-55917-8","volume":"16","author":"J Geng","year":"2025","unstructured":"Geng J, Zhang X, Guo Y, Wen H, Guo D, Liang Q, et al. Moderate-intensity interval exercise exacerbates cardiac lipotoxicity in high-fat, high-calories diet-fed mice. Nat Commun. 2025;16(1):613.","journal-title":"Nat Commun"},{"key":"2774_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fcvm.2020.00064","volume":"7","author":"Y Oishi","year":"2020","unstructured":"Oishi Y, Manabe I. Organ system crosstalk in cardiometabolic disease in the age of multimorbidity. Front Cardiovasc Med. 2020;7:64.","journal-title":"Front Cardiovasc Med"},{"key":"2774_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/17501911.2025.2489921","volume":"17","author":"N Atzemian","year":"2025","unstructured":"Atzemian N, Mohammed S, Di Venanzio L, Gorica E, Costantino S, Ruschitzka F, et al. Cardiometabolic disease management: influences from epigenetics. Epigenomics. 2025;17:463.","journal-title":"Epigenomics"},{"issue":"723","key":"2774_CR44","doi-asserted-by":"publisher","first-page":"eadf9382","DOI":"10.1126\/scitranslmed.adf9382","volume":"15","author":"MW Schleh","year":"2023","unstructured":"Schleh MW, Caslin HL, Garcia JN, Mashayekhi M, Srivastava G, Bradley AB, et al. Metaflammation in obesity and its therapeutic targeting. Sci Transl Med. 2023;15(723):eadf9382.","journal-title":"Sci Transl Med."},{"issue":"3","key":"2774_CR45","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.7150\/ijbs.105513","volume":"21","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhou W, Wang X, Men H, Wang J, Xu J, et al. Exacerbation by knocking-out metallothionein gene of obesity-induced cardiac remodeling is associated with the activation of CARD9 signaling. Int J Biol Sci. 2025;21(3):1032\u201346.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2774_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2022.159262","volume":"1868","author":"S Kersten","year":"2023","unstructured":"Kersten S. The impact of fasting on adipose tissue metabolism. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868(3): 159262.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2774_CR47","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3389\/fimmu.2019.01173","volume":"10","author":"J Lu","year":"2019","unstructured":"Lu J, Zhao J, Meng H, Zhang X. Adipose Tissue-resident immune cells in obesity and type 2 diabetes. Front Immunol. 2019;10:1173.","journal-title":"Front Immunol"},{"issue":"12","key":"2774_CR48","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s44161-024-00563-4","volume":"3","author":"JG Barcia Dur\u00e1n","year":"2024","unstructured":"Barcia Dur\u00e1n JG, Das D, Gildea M, Amadori L, Gourvest M, Kaur R, et al. Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors. Nat Cardiovasc Res. 2024;3(12):1482\u2013502.","journal-title":"Nat Cardiovasc Res"},{"issue":"5","key":"2774_CR49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/a-0892-4290","volume":"129","author":"I Baloglu","year":"2021","unstructured":"Baloglu I, Turkmen K, Selcuk NY, Tonbul HZ, Ozcicek A, Hamur H, et al. The relationship between visceral adiposity index and epicardial adipose tissue in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2021;129(5):390\u20135.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2774_CR50","doi-asserted-by":"publisher","first-page":"1167952","DOI":"10.3389\/fendo.2023.1167952","volume":"14","author":"C Li","year":"2023","unstructured":"Li C, Liu X, Adhikari BK, Chen L, Liu W, Wang Y, et al. The role of epicardial adipose tissue dysfunction in cardiovascular diseases: an overview of pathophysiology, evaluation, and management. Front Endocrinol (Lausanne). 2023;14:1167952.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"23","key":"2774_CR51","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.3390\/ijms20235989","volume":"20","author":"AC Villasante Fricke","year":"2019","unstructured":"Villasante Fricke AC, Iacobellis G. Epicardial adipose tissue: clinical biomarker of cardio-metabolic risk. Int J Mol Sci. 2019;20(23):5989.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2774_CR52","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ejhf.1283","volume":"20","author":"G van Woerden","year":"2018","unstructured":"van Woerden G, Gorter TM, Westenbrink BD, Willems TP, van Veldhuisen DJ, Rienstra M. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. Eur J Heart Fail. 2018;20(11):1559\u201366.","journal-title":"Eur J Heart Fail"},{"key":"2774_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf056","author":"C Janssen-Telders","year":"2025","unstructured":"Janssen-Telders C, Eringa EC, de Groot JR, de Man FS, Handoko ML. The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction. Cardiovasc Res. 2025. https:\/\/doi.org\/10.1093\/cvr\/cvaf056.","journal-title":"CardiovascRes"},{"key":"2774_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2840-10-2","volume":"10","author":"Y Zhou","year":"2011","unstructured":"Zhou Y, Wei Y, Wang L, Wang X, Du X, Sun Z, et al. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol. 2011;10:2.","journal-title":"Cardiovasc Diabetol"},{"issue":"13","key":"2774_CR55","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/eurheartj\/eht099","volume":"36","author":"N Venteclef","year":"2015","unstructured":"Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J. 2015;36(13):795\u2013805a.","journal-title":"Eur Heart J"},{"issue":"3","key":"2774_CR56","first-page":"112","volume":"30","author":"L Basurto Acevedo","year":"2018","unstructured":"Basurto Acevedo L, Barrera Hern\u00e1ndez S, Fern\u00e1ndez Mu\u00f1oz MJ, Saucedo Garc\u00eda RP, Rodr\u00edguez Luna AK, Mart\u00ednez MC. An increase in epicardial fat in women is associated with thrombotic risk. Clin Investig Arterioscler. 2018;30(3):112\u20137.","journal-title":"Clin Investig Arterioscler"},{"issue":"2","key":"2774_CR57","first-page":"147","volume":"100","author":"RM Agra","year":"2014","unstructured":"Agra RM, Teijeira-Fern\u00e1ndez E, Pascual-Figal D, Jes\u00fas SM, Fern\u00e1ndez-Trasancos \u00c1, Sierra J, et al. Differential behavior between S100A9 and adiponectin in coronary artery disease. Plasma Epicardial Fat Life Sci. 2014;100(2):147\u201351.","journal-title":"Plasma Epicardial Fat Life Sci"},{"issue":"1","key":"2774_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11897-025-00700-5","volume":"22","author":"J Whitman","year":"2025","unstructured":"Whitman J, Kozaily E, Michos ED, Silverman DN, Fudim M, Mentz RJ, et al. Epicardial fat in heart failure and preserved ejection fraction: novel insights and future perspectives. Curr Heart Fail Rep. 2025;22(1):13.","journal-title":"Curr Heart Fail Rep"},{"issue":"12","key":"2774_CR59","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ejhf.2741","volume":"24","author":"G van Woerden","year":"2022","unstructured":"van Woerden G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, Rienstra M, Gorter TM. Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives. Eur J Heart Fail. 2022;24(12):2238\u201350.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2774_CR60","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/ejhf.2337","volume":"23","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, Paneni F, Mazzola M, De Biase N, Del Punta L, Gargani L, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23(11):1858\u201371.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2774_CR61","doi-asserted-by":"publisher","first-page":"16501","DOI":"10.1038\/s41598-021-95534-1","volume":"11","author":"CH Yen","year":"2021","unstructured":"Yen CH, Lin JL, Sung KT, Su CH, Huang WH, Chen YY, et al. Association of free fatty acid binding protein with central aortic stiffness, myocardial dysfunction and preserved ejection fraction heart failure. Sci Rep. 2021;11(1):16501.","journal-title":"Sci Rep"},{"issue":"4","key":"2774_CR62","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/cvr\/cvae006","volume":"120","author":"Q Sun","year":"2024","unstructured":"Sun Q, G\u00fcven B, Wagg CS, Almeida de Oliveira A, Silver H, Zhang L, et al. Mitochondrial fatty acid oxidation is the major source of cardiac adenosine triphosphate production in heart failure with preserved ejection fraction. Cardiovasc Res. 2024;120(4):360\u201371.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2774_CR63","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCRESAHA.109.200501","volume":"105","author":"V Lamounier-Zepter","year":"2009","unstructured":"Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck W-H, et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction. Circ Res. 2009;105(4):326\u201334.","journal-title":"Circ Res"},{"issue":"11","key":"2774_CR64","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","volume":"118","author":"PC Schulze","year":"2016","unstructured":"Schulze PC, Drosatos K, Goldberg IJ. Lipid use and misuse by the heart. Circ Res. 2016;118(11):1736\u201351.","journal-title":"Circ Res"},{"issue":"9\u201310","key":"2774_CR65","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10495-024-01977-y","volume":"29","author":"MS D\u2019Arcy","year":"2024","unstructured":"D\u2019Arcy MS. Mitophagy in health and disease. Molecular mechanisms, regulatory pathways, and therapeutic implications. Apoptosis. 2024;29(9\u201310):1415\u201328.","journal-title":"Apoptosis"},{"issue":"11","key":"2774_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11886-020-01382-2","volume":"22","author":"EC Castillo","year":"2020","unstructured":"Castillo EC, V\u00e1zquez-Garza E, Yee-Trejo D, Garc\u00eda-Rivas G, Torre-Amione G. What is the role of the inflammation in the pathogenesis of heart failure? Curr Cardiol Rep. 2020;22(11):139.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"2774_CR67","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12880-021-00695-0","volume":"21","author":"V Tsampasian","year":"2021","unstructured":"Tsampasian V, Swift AJ, Assadi H, Chowdhary A, Swoboda P, Sammut E, et al. Myocardial inflammation and energetics by cardiac MRI: a review of emerging techniques. BMC Med Imaging. 2021;21(1):164.","journal-title":"BMC Med Imaging"},{"issue":"10","key":"2774_CR68","doi-asserted-by":"publisher","first-page":"e006240","DOI":"10.1161\/CIRCHEARTFAILURE.119.006240","volume":"12","author":"OF AbouEzzeddine","year":"2019","unstructured":"AbouEzzeddine OF, Kemp BJ, Borlaug BA, Mullan BP, Behfar A, Pislaru SV, et al. Myocardial energetics in heart failure with preserved ejection fraction. Circ Heart Fail. 2019;12(10):e006240.","journal-title":"Circ Heart Fail"},{"issue":"9","key":"2774_CR69","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/oby.2009.510","volume":"18","author":"SJ Mihalik","year":"2010","unstructured":"Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010;18(9):1695\u2013700.","journal-title":"Obesity (Silver Spring)"},{"key":"2774_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.695952","volume":"8","author":"B Tourki","year":"2021","unstructured":"Tourki B, Halade GV. Heart failure syndrome with preserved ejection fraction is a metabolic cluster of non-resolving inflammation in obesity. Front Cardiovasc Med. 2021;8: 695952.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"2774_CR71","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M, Kitzman DW. Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2. JACC Heart Fail. 2018;6(8):633\u20139.","journal-title":"JACC Heart Fail"},{"key":"2774_CR72","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fcvm.2020.00028","volume":"7","author":"SA Mohammed","year":"2020","unstructured":"Mohammed SA, Ambrosini S, L\u00fcscher T, Paneni F, Costantino S. Epigenetic control of mitochondrial function in the vasculature. Front Cardiovasc Med. 2020;7:28.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2774_CR73","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jacbts.2022.08.003","volume":"8","author":"H Liu","year":"2023","unstructured":"Liu H, Huang Y, Zhao Y, Kang GJ, Feng F, Wang X, et al. Inflammatory macrophage interleukin-1\u03b2 mediates high-fat diet-induced heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2023;8(2):174\u201385.","journal-title":"JACC Basic Transl Sci"},{"key":"2774_CR74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171874","author":"S Smolgovsky","year":"2023","unstructured":"Smolgovsky S, Bayer AL, Kaur K, Sanders E, Aronovitz M, Filipp ME, et al. Impaired T cell IRE1\u03b1\/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI171874.","journal-title":"J Clin Invest"},{"key":"2774_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.624903","volume":"11","author":"J Herold","year":"2020","unstructured":"Herold J, Kalucka J. Angiogenesis in adipose tissue: the interplay between adipose and endothelial cells. Front Physiol. 2020;11: 624903.","journal-title":"Front Physiol"},{"issue":"1","key":"2774_CR76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/cvr\/cvu172","volume":"104","author":"SG Ong","year":"2014","unstructured":"Ong SG, Lee WH, Theodorou L, Kodo K, Lim SY, Shukla DH, et al. HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc Res. 2014;104(1):24\u201336.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2774_CR77","first-page":"903","volume":"53","author":"AM Fusaru","year":"2012","unstructured":"Fusaru AM, Pisoschi CG, Bold A, Taisescu C, St\u0103nescu R, H\u00eencu M, et al. Hypoxia induced VEGF synthesis in visceral adipose depots of obese diabetic patients. Rom J Morphol Embryol. 2012;53(4):903\u20139.","journal-title":"Rom J Morphol Embryol"},{"key":"2774_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.freeradbiomed.2018.03.049","volume":"125","author":"L Glennon-Alty","year":"2018","unstructured":"Glennon-Alty L, Hackett AP, Chapman EA, Wright HL. Neutrophils and redox stress in the pathogenesis of autoimmune disease. Free Radic Biol Med. 2018;125:25\u201335.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"2774_CR79","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.3390\/ijms22083850","volume":"22","author":"DJ Medina-Leyte","year":"2021","unstructured":"Medina-Leyte DJ, Zepeda-Garc\u00eda O, Dom\u00ednguez-P\u00e9rez M, Gonz\u00e1lez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850.","journal-title":"Int J Mol Sci"},{"key":"2774_CR80","doi-asserted-by":"publisher","first-page":"1070935","DOI":"10.3389\/fcvm.2022.1070935","volume":"9","author":"A Saavedra-Alvarez","year":"2022","unstructured":"Saavedra-Alvarez A, Pereyra KV, Toledo C, Iturriaga R, Del Rio R. Vascular dysfunction in HFpEF: potential role in the development, maintenance, and progression of the disease. Front Cardiovasc Med. 2022;9:1070935.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"2774_CR81","doi-asserted-by":"publisher","first-page":"885","DOI":"10.5603\/cj.97962","volume":"31","author":"K Momot","year":"2024","unstructured":"Momot K, Wojciechowska M, Krauz K, Czarzasta K, Puchalska L, Zar\u0119bi\u0144ski M, et al. Endoplasmic reticulum stress and expression of nitric oxide synthases in heart failure with preserved and with reduced ejection fraction\u2014pilot study. Cardiol J. 2024;31(6):885\u201394.","journal-title":"Cardiol J"},{"key":"2774_CR82","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.12","volume":"8","author":"JM Bilak","year":"2022","unstructured":"Bilak JM, Alam U, Miller CA, McCann GP, Arnold JR, Kanagala P. Microvascular dysfunction in heart failure with preserved ejection fraction: pathophysiology, assessment, prevalence and prognosis. Card Fail Rev. 2022;8: e24.","journal-title":"Card Fail Rev"},{"issue":"2","key":"2774_CR83","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12471-021-01579-2","volume":"30","author":"M Wijnen","year":"2022","unstructured":"Wijnen M, Duschek EJJ, Boom H, van Vliet M. The effects of antidiabetic agents on heart failure. Neth Heart J. 2022;30(2):65\u201375.","journal-title":"Neth Heart J"},{"issue":"4","key":"2774_CR84","first-page":"1024","volume":"13","author":"CN Hsu","year":"2023","unstructured":"Hsu CN, Hsuan CF, Liao D, Chang JK, Chang AJ, Hee SW, et al. Anti-diabetic therapy and heart failure: recent advances in clinical evidence and molecular mechanism. Life (Basel). 2023;13(4):1024.","journal-title":"Life (Basel)"},{"issue":"7","key":"2774_CR85","doi-asserted-by":"publisher","first-page":"971","DOI":"10.5551\/jat.RV17064","volume":"29","author":"Y Yoshida","year":"2022","unstructured":"Yoshida Y, Shimizu I, Minamino T. Capillaries as a therapeutic target for heart failure. J Atheroscler Thromb. 2022;29(7):971\u201388.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"2774_CR86","doi-asserted-by":"publisher","first-page":"19488","DOI":"10.1038\/s41598-021-98998-3","volume":"11","author":"T Wang","year":"2021","unstructured":"Wang T, Tian J, Jin Y. VCAM1 expression in the myocardium is associated with the risk of heart failure and immune cell infiltration in myocardium. Sci Rep. 2021;11(1):19488.","journal-title":"Sci Rep"},{"key":"2774_CR87","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3389\/fimmu.2019.00823","volume":"10","author":"G Ristagno","year":"2019","unstructured":"Ristagno G, Fumagalli F, Bottazzi B, Mantovani A, Olivari D, Novelli D, et al. Pentraxin 3 in cardiovascular disease. Front Immunol. 2019;10:823.","journal-title":"Front Immunol"},{"key":"2774_CR88","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fcvm.2019.00020","volume":"6","author":"R Gogiraju","year":"2019","unstructured":"Gogiraju R, Bochenek ML, Sch\u00e4fer K. Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure. Front Cardiovasc Med. 2019;6:20.","journal-title":"Front Cardiovasc Med"},{"key":"2774_CR89","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fphys.2020.00345","volume":"11","author":"D Kolijn","year":"2020","unstructured":"Kolijn D, Kov\u00e1cs \u00c1, Herwig M, L\u00f3di M, Sieme M, Alhaj A, et al. Enhanced cardiomyocyte function in hypertensive rats with diastolic dysfunction and human heart failure patients after acute treatment with soluble guanylyl cyclase (sGC) activator. Front Physiol. 2020;11:345.","journal-title":"Front Physiol"},{"issue":"9","key":"2774_CR90","volume":"13","author":"S Kansakar","year":"2021","unstructured":"Kansakar S, Guragain A, Verma D, Sharma P, Dhungana B, Bhattarai B, et al. Soluble guanylate cyclase stimulators in heart failure. Cureus. 2021;13(9): e17781.","journal-title":"Cureus"},{"key":"2774_CR91","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fimmu.2018.00294","volume":"9","author":"JG Cho","year":"2018","unstructured":"Cho JG, Lee A, Chang W, Lee MS, Kim J. Endothelial to mesenchymal transition represents a key link in the interaction between inflammation and endothelialdysfunction. Front Immunol. 2018;9:294.","journal-title":"Front Immunol"},{"issue":"1","key":"2774_CR92","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1038\/s41598-024-55613-5","volume":"14","author":"J Shen","year":"2024","unstructured":"Shen J, Liang J, Rejiepu M, Ma Z, Zhao J, Li J, et al. Analysis of immunoinfiltration and EndoMT based on TGF-\u03b2 signaling pathway-related genes in acute myocardial infarction. Sci Rep. 2024;14(1):5183.","journal-title":"Sci Rep"},{"issue":"5","key":"2774_CR93","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41419-021-03750-4","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, He J, Wang J, Liu J, Chen Z, Deng B, et al. Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy. Cell Death Dis. 2021;12(5):470.","journal-title":"Cell Death Dis"},{"issue":"9","key":"2774_CR94","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008372","volume":"14","author":"M Valero-Mu\u00f1oz","year":"2021","unstructured":"Valero-Mu\u00f1oz M, Oh A, Faudoa E, Bret\u00f3n-Romero R, El Adili F, Bujor A, et al. Endothelial-mesenchymal transition in heart failure with a preserved ejection fraction: insights into the cardiorenal syndrome. Circ Heart Fail. 2021;14(9): e008372.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2774_CR95","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1139\/bcb-2020-0624","volume":"99","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhu Z, Wang T, Dong Y, Fan Y, Sun D. TGF-\u03b21-containing exosomes from cardiac microvascular endothelial cells mediate cardiac fibroblast activation under high glucose conditions. Biochem Cell Biol. 2021;99(6):693\u20139.","journal-title":"Biochem Cell Biol"},{"key":"2774_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117487","volume":"548","author":"V Singh","year":"2023","unstructured":"Singh V, Kaur R, Kumari P, Pasricha C, Singh R. ICAM-1 and VCAM-1: gatekeepers in various inflammatory and cardiovascular disorders. Clin Chim Acta. 2023;548: 117487.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"2774_CR97","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s10753-018-0736-4","volume":"41","author":"C Li","year":"2018","unstructured":"Li C, He J, Zhong X, Gan H, Xia Y. CX3CL1\/CX3CR1 axis contributes to angiotensin II-induced vascular smooth muscle cell proliferation and inflammatory cytokine production. Inflammation. 2018;41(3):824\u201334.","journal-title":"Inflammation"},{"issue":"18","key":"2774_CR98","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.3390\/ijms20184472","volume":"20","author":"L Zuo","year":"2019","unstructured":"Zuo L, Prather ER, Stetskiv M, Garrison DE, Meade JR, Peace TI, et al. Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments. Int J Mol Sci. 2019;20(18):4472.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2774_CR99","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1681\/ASN.0000000000000095","volume":"34","author":"S B\u00e9land","year":"2023","unstructured":"B\u00e9land S, D\u00e9sy O, El Fekih R, Marcoux M, Thivierge MP, Desgagn\u00e9 JS, et al. Expression of class II human leukocyte antigens on human endothelial cells shows high interindividual and intersubclass heterogeneity. J Am Soc Nephrol. 2023;34(5):846\u201356.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2774_CR100","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1161\/ATVBAHA.121.316600","volume":"41","author":"C Yap","year":"2021","unstructured":"Yap C, Mieremet A, de Vries CJM, Micha D, de Waard V. Six shades of vascular smooth muscle cells illuminated by KLF4 (Kr\u00fcppel-Like Factor 4). Arterioscler Thromb Vasc Biol. 2021;41(11):2693\u2013707.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"20","key":"2774_CR101","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031121","volume":"12","author":"R Chen","year":"2023","unstructured":"Chen R, McVey DG, Shen D, Huang X, Ye S. Phenotypic switching of vascular smooth muscle cells in atherosclerosis. J Am Heart Assoc. 2023;12(20): e031121.","journal-title":"J Am Heart Assoc"},{"key":"2774_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2024.106760","volume":"81","author":"N Li","year":"2025","unstructured":"Li N, Cao Y, Li Y, Zhang K, Zhang L, Luo Q, et al. Predictive value of epicardial adipose tissue volume for early detection of left ventricular dysfunction in patients suspected of coronary artery disease. Clin Radiol. 2025;81: 106760.","journal-title":"Clin Radiol"},{"key":"2774_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.719456","volume":"12","author":"M Zurek","year":"2021","unstructured":"Zurek M, Aavik E, Mallick R, Yl\u00e4-Herttuala S. Epigenetic regulation of vascular smooth muscle cell phenotype switching in atherosclerotic artery remodeling: a mini-review. Front Genet. 2021;12: 719456.","journal-title":"Front Genet"},{"issue":"12","key":"2774_CR104","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/cdd.2009.153","volume":"16","author":"L Elia","year":"2009","unstructured":"Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009;16(12):1590\u20138.","journal-title":"Cell Death Differ"},{"issue":"47","key":"2774_CR105","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1093\/eurheartj\/ehx568","volume":"39","author":"S Costantino","year":"2018","unstructured":"Costantino S, Libby P, Kishore R, Tardif JC, El-Osta A, Paneni F. Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. Eur Heart J. 2018;39(47):4150\u20138.","journal-title":"Eur Heart J"},{"issue":"20","key":"2774_CR106","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/eurheartj\/ehab197","volume":"42","author":"N Hamdani","year":"2021","unstructured":"Hamdani N, Costantino S, M\u00fcgge A, Lebeche D, Tsch\u00f6pe C, Thum T, et al. Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. Eur Heart J. 2021;42(20):1940\u201358.","journal-title":"Eur Heart J"},{"issue":"2","key":"2774_CR107","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00395-024-01093-7","volume":"120","author":"G Benincasa","year":"2025","unstructured":"Benincasa G, Pepin ME, Russo V, Cacciatore F, D\u2019Alto M, Argiento P, et al. High-resolution DNA methylation changes reveal biomarkers of heart failure with preserved ejection fraction versus reduced ejection fraction. Basic Res Cardiol. 2025;120(2):347\u201361.","journal-title":"Basic Res Cardiol"},{"key":"2774_CR108","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1038\/ncomms6288","volume":"5","author":"R Gilsbach","year":"2014","unstructured":"Gilsbach R, Preissl S, Gr\u00fcning BA, Schnick T, Burger L, Benes V, et al. Dynamic DNA methylation orchestrates cardiomyocyte development, maturation and disease. Nat Commun. 2014;5:5288.","journal-title":"Nat Commun"},{"issue":"3","key":"2774_CR109","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/cvr\/cvv015","volume":"105","author":"X Xu","year":"2015","unstructured":"Xu X, Tan X, Tampe B, Nyamsuren G, Liu X, Maier LS, et al. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res. 2015;105(3):279\u201391.","journal-title":"Cardiovasc Res"},{"key":"2774_CR110","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tox.2014.06.006","volume":"323","author":"H Tao","year":"2014","unstructured":"Tao H, Yang JJ, Chen ZW, Xu SS, Zhou X, Zhan HY, et al. DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1\/2. Toxicology. 2014;323:42\u201350.","journal-title":"Toxicology"},{"issue":"1","key":"2774_CR111","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1074248420952233","volume":"26","author":"W Cheng","year":"2021","unstructured":"Cheng W, Li X, Liu D, Cui C, Wang X. Endothelial-to-mesenchymal transition: role in cardiac fibrosis. J Cardiovasc Pharmacol Ther. 2021;26(1):3\u201311.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"34","key":"2774_CR112","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1093\/eurheartj\/ehz915","volume":"41","author":"TJ Ford","year":"2020","unstructured":"Ford TJ, Corcoran D, Padmanabhan S, Aman A, Rocchiccioli P, Good R, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. Eur Heart J. 2020;41(34):3239\u201352.","journal-title":"Eur Heart J"},{"issue":"5","key":"2774_CR113","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1002\/ehf2.12810","volume":"7","author":"CR Bain","year":"2020","unstructured":"Bain CR, Ziemann M, Kaspi A, Khan AW, Taylor R, Trahair H, et al. DNA methylation patterns from peripheral blood separate coronary artery disease patients with and without heart failure. ESC Heart Fail. 2020;7(5):2468\u201378.","journal-title":"ESC Heart Fail"},{"key":"2774_CR114","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74919","author":"M Landim-Vieira","year":"2022","unstructured":"Landim-Vieira M, Childers MC, Wacker AL, Garcia MR, He H, Singh R, et al. Post-translational modification patterns on \u03b2-myosin heavy chain are altered in ischemic and nonischemic human hearts. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.74919.","journal-title":"Elife"},{"key":"2774_CR115","doi-asserted-by":"publisher","first-page":"1133611","DOI":"10.3389\/fcvm.2023.1133611","volume":"10","author":"M Funamoto","year":"2023","unstructured":"Funamoto M, Imanishi M, Tsuchiya K, Ikeda Y. Roles of histone acetylation sites in cardiac hypertrophy and heart failure. Front Cardiovasc Med. 2023;10:1133611.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"2774_CR116","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3390\/biomedicines11102632","volume":"11","author":"N Atzemian","year":"2023","unstructured":"Atzemian N, Dovrolis N, Ragia G, Portokallidou K, Kolios G, Manolopoulos VG. Beyond the rhythm: in silico identification of key genes and therapeutic targets in atrial fibrillation. Biomedicines. 2023;11(10):2632.","journal-title":"Biomedicines"},{"issue":"6","key":"2774_CR117","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/CIRCRESAHA.122.320888","volume":"131","author":"A Mengozzi","year":"2022","unstructured":"Mengozzi A, Costantino S, Paneni F, Duranti E, Nannipieri M, Mancini R, et al. Targeting SIRT1 Rescues age- and obesity-induced microvascular dysfunction in ex vivo human vessels. Circ Res. 2022;131(6):476\u201391.","journal-title":"Circ Res"},{"key":"2774_CR118","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.freeradbiomed.2014.03.018","volume":"71","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Mi SL, Hu N, Doser TA, Sun A, Ge J, et al. Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function. Free Radic Biol Med. 2014;71:208\u201320.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2774_CR119","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12933-023-02057-2","volume":"22","author":"S Costantino","year":"2023","unstructured":"Costantino S, Mengozzi A, Velagapudi S, Mohammed SA, Gorica E, Akhmedov A, et al. Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy. Cardiovasc Diabetol. 2023;22(1):312.","journal-title":"Cardiovasc Diabetol"},{"key":"2774_CR120","doi-asserted-by":"crossref","unstructured":"Costantino S, Mohammed SA, Ambrosini S, Telesca M, Mengozzi A, Walavalkar K, et al. Chromatin rewiring by SETD2 drives lipotoxic injury in cardiometabolic HFpEF. Circ Res. 2025.","DOI":"10.1161\/CIRCRESAHA.124.325310"},{"key":"2774_CR121","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejphar.2014.01.063","volume":"728","author":"BM Patel","year":"2014","unstructured":"Patel BM, Raghunathan S, Porwal U. Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus. Eur J Pharmacol. 2014;728:128\u201334.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2774_CR122","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCRESAHA.109.208785","volume":"105","author":"W Zhu","year":"2009","unstructured":"Zhu W, Trivedi CM, Zhou D, Yuan L, Lu MM, Epstein JA. Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circ Res. 2009;105(12):1240\u20137.","journal-title":"Circ Res"},{"key":"2774_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.675724","volume":"12","author":"Y Nomura","year":"2021","unstructured":"Nomura Y, Nakano M, Woo Sung H, Han M, Pandey D. Inhibition of HDAC6 activity protects against endothelial dysfunction and Atherogenesis in vivo: a role for HDAC6 neddylation. Front Physiol. 2021;12: 675724.","journal-title":"Front Physiol"},{"key":"2774_CR124","doi-asserted-by":"publisher","DOI":"10.2337\/db24-0997","author":"SA Mohammed","year":"2025","unstructured":"Mohammed SA, Gorica E, Albiero M, Karsai G, Mengozzi A, Caravaggi CM, et al. Targeting SETD7 rescues diabetes-induced impairment of angiogenic response by transcriptional repression of semaphorin 3G. Diabetes. 2025. https:\/\/doi.org\/10.2337\/db24-0997.","journal-title":"Diabetes"},{"issue":"3","key":"2774_CR125","doi-asserted-by":"publisher","first-page":"293","DOI":"10.33594\/000000535","volume":"56","author":"JB Miranda","year":"2022","unstructured":"Miranda JB, Lunardon G, Lima VM, de Oliveira ST, Lino CA, Jensen L, et al. Set7 deletion prevents glucose intolerance and improves the recovery of cardiac function after ischemia and reperfusion in obese female mice. Cell Physiol Biochem. 2022;56(3):293\u2013309.","journal-title":"Cell Physiol Biochem"},{"issue":"12","key":"2774_CR126","first-page":"1906","volume":"130","author":"J Roh","year":"2022","unstructured":"Roh J, Hill JA, Singh A, Valero-Mu\u00f1oz M, Sam F. Heart failure with preserved ejection fraction: heterogeneous syndrome. Diverse Preclin Models Circ Res. 2022;130(12):1906\u201325.","journal-title":"Diverse Preclin Models Circ Res"},{"issue":"5","key":"2774_CR127","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/heartjnl-2016-310790","volume":"104","author":"R Zakeri","year":"2018","unstructured":"Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart. 2018;104(5):377\u201384.","journal-title":"Heart"},{"issue":"3","key":"2774_CR128","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12265-017-9756-y","volume":"10","author":"SJ Shah","year":"2017","unstructured":"Shah SJ. Precision medicine for heart failure with preserved ejection fraction: an overview. J Cardiovasc Transl Res. 2017;10(3):233\u201344.","journal-title":"J Cardiovasc Transl Res"},{"issue":"7","key":"2774_CR129","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/genes11070747","volume":"11","author":"O Strianese","year":"2020","unstructured":"Strianese O, Rizzo F,Ciccarelli M, Galasso G, D\u2019Agostino Y, Salvati A, et al. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes (Basel). 2020;11(7):747.","journal-title":"Genes (Basel)"},{"key":"2774_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.923014","volume":"9","author":"E Gorica","year":"2022","unstructured":"Gorica E, Mohammed SA, Ambrosini S, Calderone V, Costantino S, Paneni F. Epi-drugs in heart failure. Front Cardiovasc Med. 2022;9: 923014.","journal-title":"Front Cardiovasc Med"},{"key":"2774_CR131","doi-asserted-by":"publisher","first-page":"1405569","DOI":"10.3389\/fphys.2024.1405569","volume":"15","author":"J Lu","year":"2024","unstructured":"Lu J, Qian S, Sun Z. Targeting histone deacetylase in cardiac diseases. Front Physiol. 2024;15:1405569.","journal-title":"Front Physiol"},{"issue":"9","key":"2774_CR132","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/CIRCRESAHA.110.226928","volume":"108","author":"JW Gordon","year":"2011","unstructured":"Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-\u03baB in the heart: to be or not to NF-\u03baB. Circ Res. 2011;108(9):1122\u201332.","journal-title":"Circ Res"},{"key":"2774_CR133","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.yjmcc.2019.03.008","volume":"130","author":"J Yang","year":"2019","unstructured":"Yang J, He J, Ismail M, Tweeten S, Zeng F, Gao L, et al. HDAC inhibition induces autophagy and mitochondrial biogenesis to maintain mitochondrial homeostasis during cardiac ischemia\/reperfusion injury. J Mol Cell Cardiol. 2019;130:36\u201348.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"2774_CR134","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41392-021-00546-y","volume":"6","author":"I Khurana","year":"2021","unstructured":"Khurana I, Maxwell S, Royce S, Mathiyalagan P, Karagiannis T, Mazarakis N, et al. SAHA attenuates Takotsubo-like myocardial injury by targeting an epigenetic Ac\/Dc axis. Signal Transduct Target Ther. 2021;6(1):159.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2774_CR135","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","volume":"11","author":"LM Tsujikawa","year":"2019","unstructured":"Tsujikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenet. 2019;11(1):102.","journal-title":"Clin Epigenet"},{"issue":"1","key":"2774_CR136","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2014.06.008","volume":"236","author":"R Jahagirdar","year":"2014","unstructured":"Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014;236(1):91\u2013100.","journal-title":"Atherosclerosis"},{"issue":"390","key":"2774_CR137","doi-asserted-by":"publisher","first-page":"eaah5084","DOI":"10.1126\/scitranslmed.aah5084","volume":"9","author":"Q Duan","year":"2017","unstructured":"Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med. 2017;9(390):eaah5084.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2774_CR138","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-020-01199-x","volume":"20","author":"SJ Nicholls","year":"2021","unstructured":"Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, et al. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021;20(1):13.","journal-title":"Cardiovasc Diabetol"},{"key":"2774_CR139","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.yjmcc.2016.03.015","volume":"94","author":"DA Chistiakov","year":"2016","unstructured":"Chistiakov DA, Orekhov AN, Bobryshev YV. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). J Mol Cell Cardiol. 2016;94:107\u201321.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"2774_CR140","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","volume":"11","author":"A Foinquinos","year":"2020","unstructured":"Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gy\u00f6ngy\u00f6si M, et al. Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat Commun. 2020;11(1):633.","journal-title":"Nat Commun"},{"issue":"2","key":"2774_CR141","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","volume":"42","author":"S Batkai","year":"2021","unstructured":"Batkai S, Genschel C, Viereck J, Rump S, B\u00e4r C, Borchert T, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J. 2021;42(2):192\u2013201.","journal-title":"Eur Heart J"},{"issue":"35","key":"2774_CR142","doi-asserted-by":"publisher","first-page":"13027","DOI":"10.1073\/pnas.0805038105","volume":"105","author":"E van Rooij","year":"2008","unstructured":"van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13027\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2774_CR143","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","volume":"18","author":"Y Han","year":"2019","unstructured":"Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2774_CR144","volume":"15","author":"RM Dies","year":"2023","unstructured":"Dies RM, Jackson CN, Flanagan CJ, Sinnathamby ES, Spillers NJ, Potharaju P, et al. The evolving role of vericiguat in patients with chronic heart failure. Cureus. 2023;15(12): e49782.","journal-title":"Cureus"},{"issue":"Suppl D","key":"2774_CR145","doi-asserted-by":"publisher","first-page":"D278","DOI":"10.1093\/eurheartjsupp\/suad106","volume":"25","author":"SA Di Fusco","year":"2023","unstructured":"Di Fusco SA, Alonzo A, Aimo A, Matteucci A, Intravaia RCM, Aquilani S, et al. ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy. Eur Heart J Suppl. 2023;25(Suppl D):D278\u201386.","journal-title":"Eur Heart J Suppl"},{"key":"2774_CR146","doi-asserted-by":"publisher","first-page":"1335531","DOI":"10.3389\/fendo.2024.1335531","volume":"15","author":"C Chen","year":"2024","unstructured":"Chen C, Lv J, Liu C. Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA. Front Endocrinol (Lausanne). 2024;15:1335531.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2774_CR147","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/clc.22719","volume":"40","author":"BW Van Tassell","year":"2017","unstructured":"Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, Dixon DL, et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the diastolic heart failure anakinra response trial 2 (D-HART2). Clin Cardiol. 2017;40(9):626\u201332.","journal-title":"Clin Cardiol"},{"issue":"8","key":"2774_CR148","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","volume":"11","author":"BW Van Tassell","year":"2018","unstructured":"Van Tassell BW, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(8): e005036.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"2774_CR149","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","volume":"11","author":"A Alogna","year":"2023","unstructured":"Alogna A, Koepp KE, Sabbah M, Espindola Netto JM, Jensen MD, Kirkland JL, et al. Interleukin-6 in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2023;11(11):1549\u201361.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"2774_CR150","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018549","volume":"10","author":"YC Chia","year":"2021","unstructured":"Chia YC, Kieneker LM, van Hassel G, Binnenmars SH, Nolte IM, van Zanden JJ, et al. Interleukin 6 and development of heart failure with preserved ejection fraction in the general population. J Am Heart Assoc. 2021;10(11): e018549.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2774_CR151","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","volume":"30","author":"M Petrie","year":"2024","unstructured":"Petrie M, Borlaug B, Buchholtz K, Ducharme A, Hvelplund A, Ping CLS, et al. HERMES: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. J Cardiac Fail. 2024;30(1):126.","journal-title":"J Cardiac Fail"},{"issue":"7","key":"2774_CR152","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jchf.2023.03.002","volume":"11","author":"E Micha\u00eblsson","year":"2023","unstructured":"Micha\u00eblsson E, Lund LH, Hage C, Shah SJ, Voors AA, Saraste A, et al. Myeloperoxidase inhibition reverses biomarker profiles associated with clinical outcomes in HFpEF. JACC Heart Fail. 2023;11(7):775\u201387.","journal-title":"JACC Heart Fail"},{"key":"2774_CR153","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10439-1","author":"A Vacca","year":"2024","unstructured":"Vacca A, Wang R, Nambiar N, Capone F, Farrelly C, Mostafa A, et al. Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities. Heart Fail Rev. 2024. https:\/\/doi.org\/10.1007\/s10741-024-10439-1.","journal-title":"Heart Fail Rev"},{"issue":"12","key":"2774_CR154","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jacc.2022.07.011","volume":"80","author":"A La Gerche","year":"2022","unstructured":"La Gerche A, Howden EJ, Haykowsky MJ, Lewis GD, Levine BD, Kovacic JC. Heart failure with preserved ejection fraction as an exercise deficiency syndrome: JACC focus seminar 2\/4. J Am Coll Cardiol. 2022;80(12):1177\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2774_CR155","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315(1):36\u201346.","journal-title":"JAMA"},{"key":"2774_CR156","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/VHRM.S379874","volume":"19","author":"A Diab","year":"2023","unstructured":"Diab A, Dastmalchi LN, Gulati M, Michos ED. A heart-healthy diet for cardiovascular disease prevention: where are we now? Vasc Health Risk Manag. 2023;19:237\u201353.","journal-title":"Vasc Health Risk Manag"},{"key":"2774_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.853096","volume":"12","author":"MR Zielinski","year":"2022","unstructured":"Zielinski MR, Gibbons AJ. Neuroinflammation, Sleep, and circadian rhythms. Front Cell Infect Microbiol. 2022;12: 853096.","journal-title":"Front Cell InfectMicrobiol"},{"issue":"23\u201324","key":"2774_CR158","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00508-023-02195-3","volume":"135","author":"P Wiech","year":"2023","unstructured":"Wiech P, W\u00fcrzburger L, Rossi VA, Caselli S, Schmied CM, Niederseer D. Hypertensive response to exercise, hypertension and heart failure with preserved ejection fraction (HFpEF)-a continuum of disease? Wien Klin Wochenschr. 2023;135(23\u201324):685\u201395.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"2774_CR159","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.hlc.2023.11.022","volume":"33","author":"VYJ Lee","year":"2024","unstructured":"Lee VYJ, Houston L, Perkovic A, Barraclough JY, Sweeting A, Yu J, et al. The effect of weight loss through lifestyle interventions in patients with heart failure with preserved ejection fraction-A systematic review and meta-analysis of randomised controlled trials. Heart Lung Circ. 2024;33(2):197\u2013208.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"2774_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101465","volume":"4","author":"HE Billingsley","year":"2025","unstructured":"Billingsley HE, Carbone S, Driggin E, Kitzman DW, Hummel SL. Dietary interventions in heart failure with preserved ejection fraction: a scoping review. JACC Adv. 2025;4(1): 101465.","journal-title":"JACC Adv"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02774-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:02:26Z","timestamp":1751522546000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02774-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":160,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02774-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco Paneni and Era Gorica manage the collection \u201cCardiometabolic HFpEF with focus on type 2 diabetes mellitus\u201d and the co-author Francesco Paneni is also an Associate Editor of the journal. They haven't been involved in the peer review of this article. Prof. Ruschitzka has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years (remuneration for the time spent in activities, such as participation as steering committee member of clinical trials and member of the Pfizer Research Award selection committee in Switzerland, were made directly to the University of Zurich). The Department of Cardiology (University Hospital of Zurich\/University of Zurich) reports research-, educational- and\/or travel grants from Abbott, Abiomed, Alnylam, Amarin, Amgen, Astra Zeneca, At the Limits Ltd., Bayer, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, CM Microport, Concept Medical, CTI, Daiichi Sankyo, Davos Congress, Edwards Lifesciences, FomF GmbH, Hamilton Health Sciences, Holcim, IHF, Innosuisse, IumiraDX, Kantar, LabPoint, MedAlliance, Medcon International, Medical Education Global Solutions, Medtronic, MicroPort, Monocle, Novartis, Novo Nordisk, OM Pharma, Pfizer, Quintiles Switzerland Sarl, RecorMedical, Roche Diagnostics, Roche Pharma, Sahajanand IN, Sanofi, Sarstedt AG, Servier, Sorin SRM SAS, SSS Int., Terumo Deutschland, Trama Solutions, V- Wave, Vifor, ZOLL. These grants do not impact on Prof. Ruschitzka`s personal remuneration. AJF declares fees from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Roche, Vifor, and Zoll, as well as grant support by Novartis, AstraZeneca and Berlin Heart unrelated to this article. DN disclosures honoraria, consultant fees and\/or travel expenses from Abbott, Amgen, Astra Zeneca, Bristol Myers Squibb SA, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Dr. Willmar Schwabe GmbH & Co. KG, Emilwood Service Limited, Gerson Lehman Group (GLG) Consulting, Novartis, Novo Nordisk, Pfizer, walk and feel, and Zoll. FP reports receiving fees for serving on advisory boards from Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"265"}}